Singapore Clinical Trial: A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)

Singapore, June 10 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)'. The following are the other relevant details related to the trial:

Therapeutic Area: Dermatology

Trial Centre(s): National Skin Centre National University Hospital

Trial Status: NA

Principal Investigator(s): Dr Hazel Oon Dr Nisha Suyien Chandran

Published by HT Digital Content Services with permission from Health Daily Digest....